Alnylam Pharmaceuticals Inc.

News & Events

Press Releases

In The Media

1. Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

   Business Wire JUN 18, 2025 10:05 AM EDT
   − R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics...
   READ ARTICLE

2. Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

   GlobeNewswire JUN 11, 2025 7:00 AM EDT
   DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL)...
   READ ARTICLE

3. Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

   Business Wire JUN 9, 2025 6:00 AM EDT
   − First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of...
   READ ARTICLE

4. Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

   Business Wire MAY 28, 2025 8:00 AM EDT
   Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced ...
   READ ARTICLE

5. Alnylam Issues 2024 Corporate Responsibility Report

   Business Wire MAY 20, 2025 9:00 AM EDT
   – Contains New Disclosures of Company’s Impact on the Environment – Includin...
   READ ARTICLE

6. AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

   Business Wire MAY 17, 2025 5:50 AM EDT
   – Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlig...
   READ ARTICLE

7. Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

   Business Wire MAY 12, 2025 7:00 AM EDT
   Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today anno...
   READ ARTICLE

8. Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

   Business Wire MAY 5, 2025 10:00 AM EDT
   Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced ...
   READ ARTICLE

9. Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

   Business Wire MAY 1, 2025 8:00 AM EDT
   − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28...
   READ ARTICLE

10. Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

    Business Wire APR 28, 2025 8:00 AM EDT
    − Recommended Approval Based on the Pivotal HELIOS-B Phase 3 Study in which Vutrisiran Dem...
    READ ARTICLE